# Mebendazole as Adjuvant Treatment for Colon Cancer

Source: https://onco.cc/trials/nct03925662/  
OnCo record `nct03925662` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of mebendazole in colorectal cancer, run by Sherief Abd-Elsalam, now recruiting.

## Summary

Mebendazole as Adjuvant Treatment for Colon Cancer is a phase 3, randomised interventional study registered as NCT03925662 by Sherief Abd-Elsalam, with a registry enrolment figure of 40 participants, started 2019-04-01 and due to reach its primary completion in 2028-12. Interventions recorded: Folfox with avastin; Mebendazole. Conditions listed: Colorectal Cancer. Primary outcome: number of patients with tumour response. Colorectal eligibility wording from the registry: "* Colorectal cancer stage 4". Sites: Egypt. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT03925662
- Phase: 3
- Setting: Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer
- Sponsor: Sherief Abd-Elsalam
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT03925662: https://clinicaltrials.gov/study/NCT03925662

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- drugs: [Mebendazole](https://onco.cc/drugs/mebendazole/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03925662.json